Close Menu

drug development

Clinical Data, which at one point was working toward becoming a personalized medicine company, is now "considering the sale of its genetic testing and biomarker development business."

PGx & molecular Dx

The firm also said that it and NextGen Sciences have developed a protein biomarker assay method that can provide rapid, reproducible, quantitative measurement of protein expression in formalin-fixed, paraffin-embedded tissue.

Although the Pharmacogenomics Training and Research Laboratory will primarily focus on training students in the discipline, it could also enable R&D partnerships with industry players.

Snippets

Premium

Johns Hopkins University's Genetics and Public Policy Center, National Cancer Institute, Santoris, RayBiotech

The new budget and stimulus funds will fuel the Genome Atlas, a personalized medicine platform, and more grants to young investigators.

The new unit will be headquartered in San Diego and led by Arthur Levin, chief development officer of Denmark-based Santaris.

People in the News

Premium

Arthur Levin

The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.

The two-for-one split of the firm's shares took place before the opening of the market today.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.